Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astellas Pharma ADR (OP:ALPMY)

14.54 -0.02 (-0.14%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astellas Pharma ADR

< Previous 1 2 3 Next >
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Why Shares of Annexon Are Plummeting Thursday ↗
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
News headline image
Google Launches Tools To Detect Fake Images, Apple May Encounter Delays In iPhone 15 Production, Shake Shack Sees Activist Investor Proxy Fight: Today's Top Stories ↗
Bloomberg 
Via Benzinga
News headline image
Astellas' Menopause Drug Under FDA Review ↗
 
Via Benzinga
News headline image
Sutro Biopharma Stock Surges On Cancer Treatment Pact ↗
 
Via Benzinga
News headline image
Astellas's Pompe Disease Gene Therapy Trial Put On FDA Clinical Hold ↗
 
Via Benzinga
News headline image
Astellas' Menopause Drug Suffers Setback After Failed Asian Trial ↗
 
Via Benzinga
News headline image
Astellas' Menopause Drug Sores FDA Approval, After Regulatory Setback ↗
The FDA on Friday approved Japanese drugmaker Astellas Pharma Inc’s (OTC: ALPMY) (OTC: ALPMF) Veozah (fezolinetant) for hot flashes 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today ↗
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
News headline image
Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58% ↗
Astellas Pharma Inc (OTC: ALPMY) and Pfizer Inc (NYSE: PFE) announced  
Via Benzinga
News headline image
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma ↗
The company is working on a treatment for the eye disease known as geographic atrophy. 
Via Investor's Business Daily
News headline image
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move ↗
Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts. 
Via Benzinga
News headline image
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration' ↗
Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of  
Via Benzinga
News headline image
FDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer ↗
 
Via Benzinga
News headline image
Japanese Government Urges China To Release Astellas Pharma's Employee ↗
The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities.  The reasons why the person was... 
Via Benzinga
News headline image
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug ↗
 
Via Benzinga
News headline image
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation ↗
 
Via Benzinga
News headline image
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover ↗
The potential deal follows rumors last year that Merck could buy Seagen. 
Via Investor's Business Daily
News headline image
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts ↗
 
Via Benzinga
News headline image
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗
 
Via Benzinga
News headline image
Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them ↗
Super Bowl LVII aired Sunday Feb. 12, 2023 and featured dozens of commercials advertising products and showcasing new movies and television shows. The commercials also featured many celebrity cameos... 
Via Benzinga
News headline image
What Is Going on With Taysha Gene (TSHA) Stock Today? ↗
Taysha and its new partner Astellas are both speculating that Adeno Associated Viruses can create treatments for genetic diseases. 
Via InvestorPlace
News headline image
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs ↗
 
Via Benzinga
News headline image
Seagen Shares Jump On Positive Data From Urothelial Cancer Trial ↗
 
Via Benzinga
News headline image
7 Best Biotech Stocks to Buy in July 2022 ↗
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Twist Bioscience, Astellas Join Forces To Develop Cancer Targeting Antibodies ↗
 
Via Benzinga
News headline image
Astellas - Seagen's Padcev Approved In Europe For Most Common Form Of Bladder Cancer ↗
The  
Via Benzinga
News headline image
Astellas Touts Safety Data For Phase 3 Menopause Drug, Sets Up US Filing ↗
Astellas Pharma Inc (OTC: ALPMF) announced topline results from the Phase 3 SKYLIGHT 4 trial investigating the long-term safety of fezolinetant in vasomotor... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.